Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Equillium Inc

EQ
Current price
0.69 USD -0.037 USD (-5.04%)
Last closed 0.72 USD
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 24 325 812 USD
Yield for 12 month -6.26 %
1Y
3Y
5Y
10Y
15Y
EQ
21.11.2021 - 28.11.2021

Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis. It also develops EQ101 completed phase 1/2 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ302 to treat gastrointestinal indications. In addition, it serves dermatology, gastroenterology, rheumatology, hematology, transplant science, oncology, and pulmonology area. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California. Address: 2223 Avenida De La Playa, La Jolla, CA, United States, 92037

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

6.75 USD

P/E ratio

Dividend Yield

Current Year

+36 084 000 USD

Last Year

+15 759 000 USD

Current Quarter

+10 689 000 USD

Last Quarter

+9 211 000 USD

Current Year

+35 958 000 USD

Last Year

+15 641 000 USD

Current Quarter

+10 657 000 USD

Last Quarter

+9 178 000 USD

Key Figures EQ

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -13 078 000 USD
Operating Margin TTM -26.11 %
PE Ratio
Return On Assets TTM -14.31 %
PEG Ratio
Return On Equity TTM -48.17 %
Wall Street Target Price 6.75 USD
Revenue TTM 37 894 000 USD
Book Value 0.6 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY 20.4 %
Dividend Yield
Gross Profit TTM 15 759 000 USD
Earnings per share -0.35 USD
Diluted Eps TTM -0.35 USD
Most Recent Quarter I 2024
Quarterly Earnings Growth YOY
Profit Margin -32.01 %

Dividend Analytics EQ

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History EQ

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor
Payout Ratio
Last Split Date
Dividend Date

Stock Valuation EQ

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE 3.4364
Enterprise Value Revenue 0.7369
Price Sales TTM 1.8075
Enterprise Value EBITDA -2.1906
Price Book MRQ 2.9518

Financials EQ

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators EQ

For 52 weeks

0.45 USD 3.25 USD
50 Day MA 1.45 USD
Shares Short Prior Month 305 933
200 Day MA 1.22 USD
Short Ratio 3.18
Shares Short 199 544
Short Percent 1.41 %

Dynamics of changes in the value of assets

Stocks


MSFT

MSFT

446.34 USD Microsoft Corporation -3.37 (-0.75%)
Detailed analytics

ETF funds


S

SLICHA

203.95 CHF UBS SLI A-dis -0.06 (-0.02%)
Detailed analytics

Metals


Gold

2339.94 USD Gold +11.09 (+0.48%)
Detailed analytics